newsfilter
← Latest News
GlobeNewswire·

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reported 32-week data from Phase 2b RewinD-LB trial